SYBX
Synlogic Inc
$
1.500
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.500
Open
1.500
VWAP
1.50
Vol
44.99K
Mkt Cap
17.08M
Low
1.480
Amount
67.44K
EV/EBITDA(TTM)
--
Total Shares
11.71M
EV
-190.58K
EV/OCF(TTM)
--
P/S(TTM)
--
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q3
FY2024Q4
0.00
-100%
--
--
0.00
-100%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Synlogic, Inc. (SYBX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 36.31%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+36.31%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Synlogic Inc (SYBX.O) is -2.94, compared to its 5-year average forward P/E of -1.86. For a more detailed relative valuation and DCF analysis to assess Synlogic Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.86
Current PE
-2.94
Overvalued PE
-0.95
Undervalued PE
-2.77
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
108.60
Current PS
0.00
Overvalued PS
266.12
Undervalued PS
-48.93
Financials
Annual
Quarterly
FY2025Q1
YoY :
-100.00%
0.00
Total Revenue
FY2025Q1
YoY :
-91.87%
-858.00K
Operating Profit
FY2025Q1
YoY :
-101.24%
317.00K
Net Income after Tax
FY2025Q1
YoY :
-101.42%
0.03
EPS - Diluted
FY2025Q1
YoY :
-89.89%
-1.60M
Free Cash Flow
FY2025Q1
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
173.0
USD
1
6-9
Months
2.8K
USD
1
0-12
Months
111.0
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
173.0
USD
1
6-9
Months
2.8K
USD
1
0-12
Months
111.0
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SYBX News & Events
News
9.5
2024-11-12NewsfilterSynlogic Reports Third Quarter 2024 Financial Results
7.2
2024-08-08Business InsiderSYBX Stock Earnings: Synlogic Beats EPS for Q2 2024
-.-
2024-05-23Business InsiderThe Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits
Sign Up For More News
People Also Watch
EQS
EQUUS Total Return Inc
1.770
USD
+0.85%
NNVC
NanoViricides Inc
1.500
USD
-2.60%
NEPH
Nephros Inc
4.155
USD
-2.46%
MLGO
MicroAlgo Inc
10.591
USD
+4.34%
GLBZ
Glen Burnie Bancorp
3.999
USD
-1.01%
BTAI
BioXcel Therapeutics Inc
5.590
USD
-17.79%
ABVE
Above Food Ingredients Inc
1.995
USD
+13.35%
EDTK
Skillful Craftsman Education Technology Ltd
1.000
USD
0.00%
FAQ
What is Synlogic Inc (SYBX) stock price today?
The current price of SYBX is 1.5 USD — it has increased 2.74 % in the last trading day.
What is Synlogic Inc (SYBX)'s business?
What is the price predicton of SYBX Stock?
What is Synlogic Inc (SYBX)'s revenue for the last quarter?
What is Synlogic Inc (SYBX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Synlogic Inc (SYBX)'s fundamentals?
How many employees does Synlogic Inc (SYBX). have?